Empa PASS on Urinary Tract Malignancies

12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus

NCT01370005 ·Status: COMPLETED ·Phase: PHASE3

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

NCT02182830 ·Status: COMPLETED ·Phase: PHASE3

Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin.

NCT06374043 ·Status: COMPLETED ·Phase: PHASE4

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

NCT01131676 ·Status: COMPLETED ·Phase: PHASE3

Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes

NCT03132181 ·Status: COMPLETED ·Phase: PHASE2

Head-to-head Comparison of Empagliflozin and Dapagliflozin

NCT03748810 ·Status: COMPLETED

Renal Impairment in Type 2 Diabetic Subjects

NCT00554450 ·Status: COMPLETED ·Phase: PHASE1

Empagliflozin in Treatment of Peripheral Diabetic Neuropathy

NCT05977465 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD

NCT06110130 ·Status: RECRUITING ·Phase: PHASE4

EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

NCT03594110 ·Status: COMPLETED ·Phase: PHASE3

Urinary Biomarker-Based Diagnostic and Monitoring System for Chronic Kidney Disease and Real-World Effectiveness of SGLT2 Inhibitors

NCT07348484 ·Status: NOT_YET_RECRUITING

Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment

NCT00663260 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

This Study Combines Data From 3 Other Studies Testing Empagliflozin in Patients With Diabetes or With Chronic Heart Failure. The Study Looks at the Numbers of Patients Who Had Lower Limb Amputations

NCT04937816 ·Status: COMPLETED

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

NCT03492580 ·Status: COMPLETED

Effects of Empagliflozin on Endogenous Glucose Production in End Stage Renal Disease(ESRD).

NCT03713190 ·Status: COMPLETED ·Phase: PHASE2

Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration

NCT03764631 ·Status: COMPLETED

The Effects of Empagliflozin on Arterial Wall Characteristics

NCT03639545 ·Status: UNKNOWN ·Phase: PHASE4

A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus

NCT01989754 ·Status: COMPLETED ·Phase: PHASE4

A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes

NCT04098575 ·Status: COMPLETED

SGLT2 Inhibitors Prophylaxis Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease?

NCT04853615 ·Status: UNKNOWN

Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes

NCT00976495 ·Status: COMPLETED ·Phase: PHASE2

Acute Kidney Injury in Patients on Dapagliflozin and Other Antidiabetic Medications

NCT02695082 ·Status: COMPLETED

Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects

NCT03485092 ·Status: COMPLETED ·Phase: PHASE4

The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors

NCT05360615 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure

NCT05392764 ·Status: RECRUITING ·Phase: PHASE3